Treatment of resistant chronic central serous chorioretinopathy via platelet-rich plasma with electromagnetic stimulation
To evaluate whether subtenon injection of platelet-rich plasma (PRP) with retinal electromagnetic stimulation (rEMS) is effective in therapy-resistant chronic central serous chorioretinopathy (CSCR).
The study included 22 eyes with resistant chronic CSCR. Cases receiving micropulse laser or additional photodynamic therapy, subtenon PRP, and subtenon PRP + rEMS were classified as times 1, 2 and 3, respectively.
At time 3, the mean bestcorrected visual acuity was 85.7 and 97.0 letters before and after the procedures, respectively (p = 0.01). Submacular thickness improved by 17, 27 and 51% at times 1, 2 and 3 respectively.
Background: To evaluate whether subtenon injection of platelet-rich plasma (PRP) with retinal electro-magnetic stimulation (rEMS) is effective in therapy-resistant chronic central serous chorioretinopathy (CSCR).
Design: Prospective, sequential. Materials & methods: The study included 22 eyes with resistant chronic CSCR. Cases receivingmicropulse laser or additional photodynamic therapy, subtenon PRP, and subtenon PRP + rEMS were classified as times 1, 2 and 3, respectively.
Results: At time 3, the mean best-corrected visual acuity was 85.7 and 97 letters before and after the procedures, respectively (p = 0.01). Submacular thickness improved by 17, 27 and 51% at times 1, 2 and 3 respectively.
Conclusion: For treating resistant CSCR, subtenon PRP + rEMS should be considered as an effective and safe option.